Yue Han Selected Research

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

10/2023	CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months.
1/2023	CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
1/2023	Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
12/2022	Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
1/2022	Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
8/2021	Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia.
1/2021	Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.
1/2021	Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
1/2021	Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.
12/2020	Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yue Han Research Topics

Disease

63	Neoplasms (Cancer) 12/2023 - 08/2004
37	Infections 02/2024 - 02/2009
22	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2024 - 01/2011
21	Colorectal Neoplasms (Colorectal Cancer) 12/2023 - 06/2014
18	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2023 - 08/2006
17	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2023 - 02/2009
16	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2024 - 06/2013
14	Neoplasm Metastasis (Metastasis) 12/2023 - 07/2015
13	Aplastic Anemia (Anemia, Hypoplastic) 05/2024 - 11/2014
13	Hemorrhage 12/2023 - 11/2014
12	Thrombocytopenia (Thrombopenia) 11/2022 - 05/2015
11	Inflammation (Inflammations) 03/2024 - 11/2011
11	Thrombotic Microangiopathies 01/2023 - 11/2017
10	Thrombosis (Thrombus) 01/2023 - 10/2009
9	Leukemia 03/2024 - 11/2011
9	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 12/2016
8	Sepsis (Septicemia) 10/2022 - 10/2016
8	Chronic Hepatitis B 10/2021 - 09/2007
7	Hypoxia (Hypoxemia) 12/2023 - 12/2016
7	Port-Wine Stain (Nevus Flammeus) 11/2023 - 03/2019
7	Residual Neoplasm 01/2023 - 11/2011
7	Hypertension (High Blood Pressure) 01/2022 - 07/2013
6	Periodontitis 03/2024 - 10/2022
6	Philadelphia Chromosome 10/2023 - 10/2013
6	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 11/2013
6	Hematologic Neoplasms (Hematological Malignancy) 02/2022 - 10/2009
6	Disseminated Intravascular Coagulation 12/2021 - 08/2012
5	Thrombotic Thrombocytopenic Purpura 01/2023 - 09/2012
5	Hepatitis B 01/2022 - 01/2017
5	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2022 - 06/2001
5	Acute Promyelocytic Leukemia 12/2021 - 08/2012
4	Viremia 03/2024 - 09/2008
4	Bacterial Infections (Bacterial Infection) 11/2023 - 11/2017
4	Heart Failure 01/2022 - 01/2018
4	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 07/2016
4	Carcinogenesis 01/2021 - 04/2015
4	Vascular Remodeling 01/2021 - 02/2011
3	Breast Neoplasms (Breast Cancer) 12/2023 - 01/2017
3	Carcinoma (Carcinomatosis) 10/2023 - 08/2004
3	Atopic Dermatitis (Atopic Eczema) 08/2023 - 01/2017
3	Hyperplasia 01/2022 - 08/2004
3	Critical Illness (Critically Ill) 01/2022 - 07/2016
3	Cognitive Dysfunction 01/2022 - 01/2019

Drug/Important Bio-Agent (IBA)

14	Biomarkers (Surrogate Marker)IBA 12/2023 - 09/2007
14	Long Noncoding RNAIBA 10/2023 - 10/2017
14	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
12	VaccinesIBA 04/2021 - 05/2006
11	Decitabine FDA Link 01/2023 - 06/2013
9	AntigensIBA 01/2022 - 08/2006
8	Chimeric Antigen ReceptorsIBA 10/2023 - 01/2019
8	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2013
7	NucleotidesIBA 10/2021 - 01/2011
6	AntibodiesIBA 05/2024 - 01/2018
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2023 - 06/2015
6	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2023 - 01/2013
6	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2017
6	Dacarbazine (DIC)FDA LinkGeneric 12/2021 - 04/2005
5	LipopolysaccharidesIBA 03/2024 - 11/2017
5	Hemostatics (Antihemorrhagics)IBA 01/2023 - 08/2012
5	RNA (Ribonucleic Acid)IBA 01/2022 - 04/2015
5	Inosine Triphosphate (ITP)IBA 01/2022 - 06/2001
4	LigandsIBA 03/2024 - 05/2019
4	CytokinesIBA 03/2024 - 08/2004
4	LipidsIBA 11/2023 - 12/2014
4	SteroidsIBA 01/2023 - 04/2012
4	BilirubinIBA 01/2023 - 07/2017
4	CateninsIBA 01/2023 - 01/2018
4	thiamine triphosphorate (TTP)IBA 01/2023 - 07/2011
4	Peptides (Polypeptides)IBA 02/2022 - 11/2011
4	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 12/2021 - 01/2020
4	Hepatitis B e AntigensIBA 10/2021 - 08/2013
4	Cisplatin (Platino)FDA LinkGeneric 02/2021 - 11/2013
4	HDL LipoproteinsIBA 01/2021 - 10/2015
4	Untranslated RNA (Noncoding RNA)IBA 01/2021 - 10/2017
3	Serine Proteases (Serine Protease)IBA 01/2024 - 01/2018
3	Therapeutic UsesIBA 12/2023 - 01/2013
3	Phosphotransferases (Kinase)IBA 12/2023 - 01/2021
3	Anti-Bacterial Agents (Antibiotics)IBA 11/2023 - 11/2017
3	Acetylcysteine (Siran)FDA LinkGeneric 01/2023 - 01/2022
3	CollagenIBA 01/2023 - 12/2020
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2022 - 08/2004
3	Thrombin FDA Link 01/2022 - 08/2014
3	Immunoglobulin G (IgG)IBA 01/2022 - 12/2019
3	Surface Antigens (Surface Antigen)IBA 01/2022 - 12/2011
3	Sorafenib (BAY 43-9006)FDA Link 05/2021 - 12/2016

Therapy/Procedure

57	Hematopoietic Stem Cell Transplantation 05/2024 - 08/2006
52	Therapeutics 12/2023 - 05/2002
30	Transplantation 10/2023 - 02/2009
16	Stem Cell Transplantation 10/2023 - 01/2016
15	Drug Therapy (Chemotherapy) 12/2023 - 01/2011
7	Cell Transplantation 03/2024 - 10/2013
7	Immunotherapy 01/2023 - 12/2018
5	Induction Chemotherapy 12/2023 - 11/2011
5	Radiofrequency Ablation 01/2019 - 04/2012
4	Length of Stay 01/2023 - 01/2019
4	Ligation 01/2023 - 01/2018
4	Photochemotherapy (Photodynamic Therapy) 03/2022 - 06/2019
3	Platelet Transfusion (Blood Platelet Transfusions) 12/2023 - 11/2014
3	Salvage Therapy 01/2023 - 01/2020
3	Punctures 01/2022 - 04/2012